Biotech News

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Regeneron Pharmaceuticals (REGN)investor.regeneron.com2026-05-22 19:05 ESTCompany update

TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biologics-driven biopharmaceutical company built around antibody science, specialty-market execution, and a durable R&D engine. Investors watch both the commercial base and the next wave of pipeline readouts.

Recent company news

REGNRegeneron Pharmaceuticals2026-06-04 15:05:54 EST

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

REGNRegeneron Pharmaceuticals2026-05-29 00:03:44 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGNRegeneron Pharmaceuticals2026-05-22 01:02:40 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGNRegeneron Pharmaceuticals2026-05-18 15:01:45 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States